NCT06821464

A Trial of HRS-9813 in Healthy Subjects

Safety, Tolerability and Pharmacokinetics of HRS-9813 After Multiple Oral Administration in Healthy Subjects-A Phase I Clinical Study

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The study is being conducted to evaluate the safety and pharmacokinetics of HRS-9813 after multiple oral administration in healthy subjects.

Conditions

• Idiopathic Pulmonary Fibrosis/Progressive Pulmonary Fibrosis

Interventions

Type	Name	Description
DRUG	HRS-9813	Initial dose to planned dose（low dose）
DRUG	HRS-9813	Initial dose to planned dose（high dose）

Timeline

• Start date: 2025-02-17
• Primary completion: 2025-06-01
• Completion: 2025-07-01
• First posted: 2025-02-12
• Last updated: 2025-05-07

Locations

1 site across 1 country: China